{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:03:38Z","timestamp":1794542618970,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sclerostin, which has three loops, inhibits bone formation and impairs whole-body lipid and glucose metabolism. The marketed therapeutic sclerostin antibody for postmenopausal osteoporosis (POP) mainly targeting loop2 promotes bone formation and improves whole-body lipid and glucose metabolism. However, FDA\/EMA warns of its cardiovascular risk. We previously demonstrate that sclerostin loop3 contributes to the inhibitory effect of sclerostin on bone formation but not its cardioprotective effect. Here we find elevated serum sclerostin levels in both POP-T2DM patients and newly-diagnosed T2DM patients and further demonstrate that sclerostin loop3 participates in the impairment effect of sclerostin on whole-body lipid and glucose metabolism in vivo. Mechanistically, specific blockade of adipocytic sclerostin loop3-LRP4 interaction attenuates the impairment effect of sclerostin on lipid and glucose metabolism in vitro and in vivo. This study provides an innovative strategy, blocking adipocytic sclerostin loop3-LRP4 interaction, to normalize lipid and glucose metabolism in POP-T2DM patients, in cardiovascular safety.<\/jats:p>","DOI":"10.1038\/s41467-026-68526-w","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:26:29Z","timestamp":1768577189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism"],"prefix":"10.1038","volume":"17","author":[{"given":"Hewen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-4199","authenticated-orcid":false,"given":"Sifan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-8497","authenticated-orcid":false,"given":"Chuanxin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meishen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongguang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-5695","authenticated-orcid":false,"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-6719","authenticated-orcid":false,"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-7871","authenticated-orcid":false,"given":"Zongkang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-0494","authenticated-orcid":false,"given":"Aiping","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1430-3224","authenticated-orcid":false,"given":"Hui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-5408","authenticated-orcid":false,"given":"Dijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2403-8156","authenticated-orcid":false,"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7807-7695","authenticated-orcid":false,"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1421-0212","authenticated-orcid":false,"given":"Bao-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"68526_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.15605\/jafes.038.AFES.18","volume":"38","author":"DMA Bernard","year":"2023","unstructured":"Bernard, D. M. A. et al. Type 2 diabetes and osteosarcopenia: double trouble? A cross-sectional pilot study in Malaysia. J. ASEAN Federation Endocr. Soc. 38, 18\u201318 (2023).","journal-title":"J. ASEAN Federation Endocr. Soc."},{"key":"68526_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6823-14-33","volume":"14","author":"G Leidig-Bruckner","year":"2014","unstructured":"Leidig-Bruckner, G. et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr. Disord. 14, 1\u201313 (2014).","journal-title":"BMC Endocr. Disord."},{"key":"68526_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.531904","volume":"12","author":"Y Wen","year":"2021","unstructured":"Wen, Y. et al. Correlation of osteoporosis in patients with newly diagnosed type 2 diabetes: a retrospective study in Chinese population. Front. Endocrinol. 12, 531904 (2021).","journal-title":"Front. Endocrinol."},{"key":"68526_CR4","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.2147\/DMSO.S305831","volume":"14","author":"J Li","year":"2021","unstructured":"Li, J., Ren, Y., Li, S. & Li, J. Relationship between sclerostin (SOST) expression and genetic loci rs851056, rs1230399 polymorphisms and bone mineral density in postmenopausal women with type 2 diabetes in Xinjiang. Diab. Metab. Syndr. Obes. 14, 4443\u20134450 (2021).","journal-title":"Diab. Metab. Syndr. Obes."},{"key":"68526_CR5","first-page":"565","volume":"7","author":"AD Shah","year":"2015","unstructured":"Shah, A. D., Shoback, D. & Lewiecki, E. M. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int. J. Women\u2019s. Health 7, 565\u2013580 (2015).","journal-title":"Int. J. Women\u2019s. Health"},{"key":"68526_CR6","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1530\/JME-18-0176","volume":"62","author":"G Holdsworth","year":"2019","unstructured":"Holdsworth, G., Roberts, S. J. & Ke, H. Z. Novel actions of sclerostin on bone. J. Mol. Endocrinol. 62, R167\u2013R185 (2019).","journal-title":"J. Mol. Endocrinol."},{"key":"68526_CR7","doi-asserted-by":"publisher","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","volume":"285","author":"C Krause","year":"2010","unstructured":"Krause, C. et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J. Biol. Chem. 285, 41614\u201341626 (2010).","journal-title":"J. Biol. Chem."},{"key":"68526_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","volume":"37","author":"SM Krishna","year":"2017","unstructured":"Krishna, S. M. et al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler Thromb. Vasc. Biol. 37, 553 (2017).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"68526_CR9","unstructured":"Bovijn, J. et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci. Transl. Med. 12, eaay6570 (2020)."},{"key":"68526_CR10","doi-asserted-by":"publisher","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","volume":"114","author":"SP Kim","year":"2017","unstructured":"Kim, S. P. et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc. Natl. Acad. Sci. USA 114, E11238\u2013E11247 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68526_CR11","doi-asserted-by":"crossref","unstructured":"Jiang, H. et al. The role of sclerostin in lipid and glucose metabolism disorders. Biochem. Pharmacol. 215, 115694 (2023).","DOI":"10.1016\/j.bcp.2023.115694"},{"key":"68526_CR12","doi-asserted-by":"publisher","first-page":"10890","DOI":"10.1074\/jbc.M807994200","volume":"284","author":"V Veverka","year":"2009","unstructured":"Veverka, V. et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890\u201310900 (2009).","journal-title":"J. Biol. Chem."},{"key":"68526_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"68526_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka, S. & Matsumoto, T. Sclerostin: from bench to bedside. J. Bone Min. Metab. 39, 332\u2013340 (2021).","journal-title":"J. Bone Min. Metab."},{"key":"68526_CR15","doi-asserted-by":"publisher","first-page":"10890","DOI":"10.1074\/jbc.M807994200","volume":"284","author":"V Veverka","year":"2009","unstructured":"Veverka, V. et al. Characterization of the structural features and interactions of sclerostin. J. Biol. Chem. 284, 10890\u201310900 (2009).","journal-title":"J. Biol. Chem."},{"key":"68526_CR16","unstructured":"Food U, Administration D. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. News Release 9, (2019)."},{"key":"68526_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s10020-024-00933-5","volume":"30","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. SOST\/Sclerostin impairs the osteogenesis and angiogesis in glucocorticoid-associated osteonecrosis of femoral head. Mol. Med. 30, 167 (2024).","journal-title":"Mol. Med."},{"key":"68526_CR18","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1161\/ATVBAHA.122.317635","volume":"42","author":"J Golledge","year":"2022","unstructured":"Golledge, J. & Thanigaimani, S. Role of sclerostin in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 42, e187\u2013e202 (2022).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"68526_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31997-8","volume":"13","author":"YY Yu","year":"2022","unstructured":"Yu, Y. Y. et al. Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nat. Commun. 13, 4241 (2022).","journal-title":"Nat. Commun."},{"key":"68526_CR20","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.7150\/thno.63177","volume":"12","author":"LY Wang","year":"2022","unstructured":"Wang, L. Y. et al. Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice. Theranostics 12, 5645\u20135674 (2022).","journal-title":"Theranostics"},{"key":"68526_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116414","volume":"271","author":"S Yu","year":"2024","unstructured":"Yu, S. et al. Discovery of the small molecular inhibitors against sclerostin loop3 as potential anti-osteoporosis agents by structural based virtual screening and molecular design. Eur. J. Med. Chem. 271, 116414 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"68526_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52965-4","volume":"15","author":"C Zhong","year":"2024","unstructured":"Zhong, C. et al. Targeting osteoblastic 11\u03b2-HSD1 to combat high-fat diet-induced bone loss and obesity. Nat. Commun. 15, 8588 (2024).","journal-title":"Nat. Commun."},{"key":"68526_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102073","volume":"34","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. A bimolecular modification strategy for developing long-lasting bone anabolic aptamer. Mol. Ther. Nucleic Acids 34, 102073 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"68526_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1048148","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating proteins: the present and the future. Front. Cell Dev. Biol. 10, 1048148 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"68526_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis, T. et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65, 1251\u20131261 (2022).","journal-title":"Diabetologia"},{"key":"68526_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100944","volume":"28","author":"Y Alhindi","year":"2022","unstructured":"Alhindi, Y. & Avery, A. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis. Contemp. Clin. Trials Commun. 28, 100944 (2022).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"68526_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding, J. P. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989 (2021).","journal-title":"N. Engl. J. Med."},{"key":"68526_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1101\/gad.180885.111","volume":"26","author":"Y Zong","year":"2012","unstructured":"Zong, Y. et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev. 26, 247\u2013258 (2012).","journal-title":"Genes Dev."},{"key":"68526_CR29","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1074\/jbc.RA118.006769","volume":"294","author":"SP Kim","year":"2019","unstructured":"Kim, S. P. et al. Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin\u2019s endocrine effects on body composition and glucose metabolism. J. Biol. Chem. 294, 6899\u20136911 (2019).","journal-title":"J. Biol. Chem."},{"key":"68526_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00018-022-04127-2","volume":"79","author":"S Katchkovsky","year":"2022","unstructured":"Katchkovsky, S., Chatterjee, B., Abramovitch-Dahan, C. V., Papo, N. & Levaot, N. Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions. Cell Mol. Life Sci. 79, 113 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"68526_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","volume":"97","author":"A Garc\u00eda-Mart\u00edn","year":"2012","unstructured":"Garc\u00eda-Mart\u00edn, A. et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus.  J. Clin. Endocrinol. Metab. 97, 234\u2013241 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"68526_CR32","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1210\/jc.2012-1901","volume":"97","author":"A Gaudio","year":"2012","unstructured":"Gaudio, A. et al. Sclerostin levels associated with inhibition of the Wnt\/\u03b2-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.  J. Clin. Endocrinol. Metab. 97, 3744\u20133750 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"68526_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(15)00508-2","volume":"4","author":"X Huo","year":"2016","unstructured":"Huo, X. et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diab. Endocrinol. 4, 115\u2013124 (2016).","journal-title":"Lancet Diab. Endocrinol."},{"key":"68526_CR34","doi-asserted-by":"crossref","unstructured":"Gilbert ZA, Muller A, Leibowitz JA, Kesselman MM. Osteoporosis prevention and treatment: the risk of comorbid cardiovascular events in postmenopausal women. Cureus 14, e24117 (2022).","DOI":"10.7759\/cureus.24117"},{"key":"68526_CR35","unstructured":"(FDA) USFaDA. Press Announcements: FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. https:\/\/www.fda.gov9, (2019)."},{"key":"68526_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12933-023-02043-8","volume":"22","author":"S Gonz\u00e1lez-Salvatierra","year":"2023","unstructured":"Gonz\u00e1lez-Salvatierra, S. et al. Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells. Cardiovasc Diabetol. 22, 301 (2023).","journal-title":"Cardiovasc Diabetol."},{"key":"68526_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki, T. et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.  Lancet Diab. Endocrinol. 10, 193\u2013206 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"68526_CR38","doi-asserted-by":"crossref","unstructured":"Hansen, M. S. et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 72, 102624 (2024).","DOI":"10.1016\/j.eclinm.2024.102624"},{"key":"68526_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jbmr.4193","volume":"36","author":"M Gerbaix","year":"2021","unstructured":"Gerbaix, M., Ammann, P. & Ferrari, S. Mechanically driven counter-regulation of cortical bone formation in response to sclerostin-neutralizing antibodies. J. Bone Min. Res. 36, 385\u2013399 (2021).","journal-title":"J. Bone Min. Res."},{"key":"68526_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12010-018-2806-3","volume":"187","author":"R Jiang","year":"2019","unstructured":"Jiang, R. et al. One-step bioprocess of inulin to product inulo-oligosaccharides using bacillus subtilis secreting an extracellular endo-inulinase. Appl. Biochem. Biotechnol. 187, 116\u2013128 (2019).","journal-title":"Appl. Biochem. Biotechnol."},{"key":"68526_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-0716-1835-6_11","volume":"2400","author":"S Lyu","year":"2022","unstructured":"Lyu, S., Zhang, C., Hou, X. & Wang, A. Tag-based pull-down assay. Methods Mol. Biol. 2400, 105\u2013114 (2022).","journal-title":"Methods Mol. Biol."},{"key":"68526_CR42","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/jcb.25432","volume":"117","author":"M Ukita","year":"2016","unstructured":"Ukita, M., Yamaguchi, T., Ohata, N. & Tamura, M. Sclerostin enhances adipocyte differentiation in 3T3-L1 cells. J. Cell Biochem. 117, 1419\u20131428 (2016).","journal-title":"J. Cell Biochem."},{"key":"68526_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102146","volume":"35","author":"A Gubu","year":"2024","unstructured":"Gubu, A. et al. Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential. Mol. Ther. Nucleic Acids 35, 102146 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"68526_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/B978-0-12-411619-1.00006-9","volume":"537","author":"SD Parlee","year":"2014","unstructured":"Parlee, S. D., Lentz, S. I., Mori, H. & MacDougald, O. A. Quantifying size and number of adipocytes in adipose tissue. Methods Enzymol. 537, 93\u2013122 (2014).","journal-title":"Methods Enzymol."},{"key":"68526_CR45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00223-015-9975-7","volume":"96","author":"S Lin","year":"2015","unstructured":"Lin, S. et al. The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats. Calcif. Tissue Int. 96, 541\u2013551 (2015).","journal-title":"Calcif. Tissue Int."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68526-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68526-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68526-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:02:12Z","timestamp":1771426932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68526-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68526"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68526-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1812"}}